| Postpartum depression (adults) (label). View labelExact | Recommended dosage is 50 mg once daily in the evening for 14 days, taken with fat-containing food (label). | Neuroactive steroid and GABA-A receptor positive allosteric modulator. FDA-approved as a 14-day oral treatment course for postpartum depression (label). | CYP3A4 | Single-dose range 19.7–24.6 h | No | | - Counsel on driving restrictions (boxed warning) and assess next-morning sedation or confusion during the 14-day course (label).
- Avoid alcohol and other CNS depressants; review other sedating medications and adjust the regimen when feasible (label/clinical).
- Monitor mood and suicidality as part of standard depression care, and ensure a practical support plan for sleep and infant-care needs (label/clinical).
- Re-check renal/hepatic status and CYP3A4 interactions to ensure the labeled dose is used (label).
| No | 2026-02-22 |
|---|
| MDD; OCD; panic disorder; PTSD; social anxiety disorder. View labelExact | Start 50 mg once daily for major depressive disorder (clinical depression) or anxiety; titrate by 25–50 mg increments every ≥1 week to 100–200 mg/day (max 200 mg/day). | Selective serotonin reuptake inhibitor (SSRI). | Multiple CYPs | Steady-state mean 26 h | No | — | - Suicidality and psychiatric activation during initiation and dose changes, especially in younger patients and in bipolar-spectrum illness.
- Sodium in older adults or patients on diuretics if symptoms suggest hyponatremia (confusion, fatigue, falls).
- Bleeding/bruising risk when combined with NSAIDs, antiplatelets, or anticoagulants; reinforce early symptom reporting.
- Medication reconciliation when TCAs, antipsychotics, or other serotonergic agents are co-prescribed; anticipate switching washout needs when regimens change.
| No | 2025-12-28 |
|---|
| Major depressive disorder; OCD; panic disorder; use with olanzapine for bipolar depression. View labelExact | Typical adult start is 20 mg once daily (often morning); may increase to 40–60 mg/day after several weeks if needed and tolerated. | Selective serotonin reuptake inhibitor (SSRI). | CYP2D6 (inhibitor) | No | — | - Suicidality and psychiatric activation (anxiety, agitation, mood elevation) during initiation and dose changes, especially in younger patients.
- Sodium in older adults or patients on diuretics if symptoms suggest hyponatremia (confusion, fatigue, gait change).
- Bleeding/bruising risk when combined with NSAIDs, antiplatelets, or anticoagulants; early symptom reporting is often reinforced.
- Medication reconciliation to avoid serotonergic combinations and to anticipate prolonged interaction windows after stopping.
| No | 2026-02-01 |
|---|
| Major depressive disorder; generalized anxiety disorder. View labelExact | Typical adult start is 10 mg once daily; may increase to 20 mg/day after ≥1 week if needed and tolerated. | Selective serotonin reuptake inhibitor (SSRI). | CYP2C19, CYP2D6 (minor), CYP3A4 (minor) | Single-dose mean 27 h; Single-dose range 27–32 h; Steady-state mean 30 h | No | — | - Suicidality and psychiatric activation (anxiety, agitation, mood elevation) during initiation and dose changes, especially in younger patients.
- Sodium in older adults or patients on diuretics if symptoms suggest hyponatremia.
- Bleeding/bruising risk when combined with NSAIDs, antiplatelets, or anticoagulants; reinforce early symptom reporting.
- Medication reconciliation to avoid serotonergic combinations and to anticipate washout needs during antidepressant switching.
- ECG when cardiac risk is present or when combining multiple QT-active medications, even though escitalopram’s QT effect is typically smaller than citalopram.
| No | 2026-02-12 |
|---|